Showing 1 - 3 results of 3 for search 'Hany Elmaraghy', query time: 0.01s Refine Results
  1. 1
    Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results from phase-3 randomized ADvocate1 and ADvocate2 studies in patients with moderate-to-severe atopic dermatitis

    Lebrikizumab is associated with improvements in patient-reported symptoms and quality-of-life measures across Eczema Area and Severity Index response categories: pooled results fro... by Andrew Blauvelt, Leon Kircik, Todd Schlesinger, Evangeline Pierce, Russel Burge, Michael Behling, Amber Reck Atwater, Hany ElMaraghy, April Armstrong

    Published 2025-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials

    Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials by Jennifer Soung, Sonja Ständer, Jan Gutermuth, Ignasi Pau-Charles, Zach Dawson, Fan Emily Yang, Luna Sun, Evangeline Pierce, Hany Elmaraghy, Linda Stein-Gold

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials

    Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized phase 3 clinical trials by Adelaide A. Hebert, Carsten Flohr, H. Chih-ho Hong, Alan D. Irvine, Evangeline Pierce, Hany Elmaraghy, Sreekumar Pillai, Zach Dawson, Sherry Chen, Clara Armengol, Elaine Siegfried, Stephan Weidinger

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: